Boundless Bio lays off 33% of staff as lead program stumbles
Boundless Bio is in a bind. A phase 1/2 trial has revealed the shortcomings of Boundless’ lead candidate, prompting the company to lay off one-third of its staff and pivot to a combination of two molecules that struggled as monotherapies.
Boundless Bio is in a bind. A phase 1/2 trial has revealed the shortcomings of Boundless’ lead candidate, prompting the company to lay off one-third of its staff and pivot to a combination of two molecules that struggled as monotherapies.
